Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Adults who survived childhood cancer and were treated with anthracyclines show significant cardiometabolic risks — yet most have little awareness of these dangers. A new population-based study found that 27% had abnormalities in heart size or function, and only 10% could identify cardiac late effects as a concern. Researchers are calling for structured cardiac surveillance and better survivor education.
Adults who survived childhood cancer and received anthracycline-based chemotherapy are carrying a significant — and largely unrecognized — cardiovascular burden, according to a new population-based study published in the Journal of Pediatric Hematology/Oncology. Researchers in Iceland evaluated 60 adult survivors (ages 20–48) treated at a pediatric oncology center between 1981 and 2011, linking medical records with self-reported data and clinical assessments from a dedicated Late Effects Center.
The findings paint a concerning picture: more than a quarter of survivors showed abnormalities in heart size or function, and one in five met criteria for metabolic syndrome. Despite these risks, awareness was strikingly low — only 10% of participants identified cardiac issues as a potential late effect of their cancer treatment.
By the Numbers:
Why it matters: As childhood cancer survival rates improve, long-term cardiovascular complications from treatment are becoming a growing concern. This study highlights a critical gap in follow-up care — survivors aren't being monitored closely enough, and many don't know what to watch for. Structured cardiac surveillance and targeted education could make a real difference in long-term outcomes for this population.
